Yikes- FluMist and measles-mumps-rubella and varicella vaccines simultaneously

[Guest guest]

Why on earth would they even do this? Infants "tolerated it well"....meaning they didn't die on the table? This is just crazy. Also, why is the FluLaval only for 18 years of age and older? What is in it?..scary. http://www.tradingmarkets.com/tm.site/news/BREAKING%20NEWS/240259/ MedImmune Reports New Data From Pediatric Studies With FluMist - UpdateMonday, May 01, 2006; Posted: 12:40 PM (RTTNews) - Monday, MedImmune Inc. (MEDI | charts | news | PowerRating) provided additional data from Pediatric studies regarding the direct and indirect effects of administering FluMist to school children as well as the safety and immunogenicity of simultaneous administration

of FluMist along with measles-mumps-rubella and varicella vaccines. FluMist, which is the first innovation in influenza vaccine technology, is a well-tolerated and effective needle-free option for immunizing healthy children and adults aged 5 to 49 years. There are currently three licensed manufacturers of Influenza Virus Vaccine namely Chiron Corp., which manufactures Fluvirin, Aventis Pasteur, Inc. manufacturing Fluzone and MedImmune, Inc., which manufactures FluMist. Earlier in March, GlaxoKline, the world's second largest drugmaker, submitted a Biologics License Application for Influenza Virus Vaccine - FluLaval to the FDA. If licensed, FluLaval will be used for the active immunization of adults 18 years of age and older. Results from the study proved that vaccinating school children with FluMist made them less

prone to influenza-like illnesses, less prescription and non- prescription drug use, lower school absentee rates and fewer missed workdays for adults in the household. Reports say that children who received FluMist had 93% fewer cases of influenza than the children who received a placebo. Another study, which was conducted to evaluate the safety and immunogenicity of administering FluMist and measles-mumps-rubella and varicella vaccines simultaneously, proved that concurrent administration of the vaccines was well tolerated in infants 12 to 15 months of age. Immunogenicity was the same when the vaccines were administered simultaneously or separately. In addition, results from post- marketing evaluation study, which was conducted to assess the long-term safety of FluMist in healthy people 5 to 49 years of age were consistent with the results of pre-licensure clinical

trials of FluMist. MEDI is currently down 1.62% or $0.51 trading at $30.96 on a volume of 580,713 shares.

Messenger with Voice. Make PC-to-Phone Calls to the US (and 30+ countries) for 2¢/min or less.